Leveraging Physiologically Based Modelling to Provide Insights on the Absorption of Paliperidone Extended-Release Formulation under Fed and Fasting Conditions.
Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 62% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 4 institutions in 3 countries.
Saima SubhaniCenter for Pharmacometrics and System Pharmacology at Lake Nona (Orlando), Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA.
Viera LukacovaSimulations Plus, Lancaster, CA 93534, USA.
Chaejin KimCenter for Pharmacometrics and System Pharmacology at Lake Nona (Orlando), Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA.
Leyanis Rodriguez-VeraCenter for Pharmacometrics and System Pharmacology at Lake Nona (Orlando), Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA.ORCID 0000-0003-1688-7008
Paula MunizModel Informed Development, CTI Laboratories Spain, Derio, 48160 Bizkaia, Spain.
Rodrigo CristofolettiCenter for Pharmacometrics and System Pharmacology at Lake Nona (Orlando), Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA.
Sandra Van OsSynthon BV, 6545 CM Nijmegen, The Netherlands.
Elena SuarezPharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Department of Pharmacology, School of Medicine and Nursing, University of the Basque Country UPV/EHU, 48940 Bizkaia, Spain.ORCID 0000-0002-6683-4847
Stephan SchmidtCenter for Pharmacometrics and System Pharmacology at Lake Nona (Orlando), Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA.ORCID 0000-0002-4998-1167
Valvanera VozmedianoCenter for Pharmacometrics and System Pharmacology at Lake Nona (Orlando), Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA.ORCID 0000-0002-2636-1889
University of Florida · USSimulations Plus (United States) · USSynthon (Netherlands) · NLUniversity of the Basque Country · ES
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Paliperidone was approved by the US FDA in 2006 as an extended-release (ER) tablet (Invega
Indexed as
food effectmechanistic absorptionphysiologically based absorption modellingregional absorption
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Leveraging Physiologically Based Modelling to Provide Insights on the Absorption of Paliperidone Extended-Release Formulation under Fed and Fasting Conditions. · full record | OpenQuestion